NICE recommends PTC Therapeutics Duchenne muscular dystrophy treatment

PTC Therapeutics has announced that NICE has issued final guidance recommending Translarna for ambulatory patients aged five and over with nonsense mutation Duchenne muscular dystrophy in connection with a managed access agreement with NHS England. Duchenne muscular dystrophy, a rare genetic disease that primarily affects males, is a progressive muscular disorder caused by the lack

Continue Reading

Takeda to Initiate World’s First Norovirus Vaccine Field Trial

Takeda has initiated a clinical trial testing the potential of the world’s first experimental vaccine for norovirus, which is responsible for nearly three quarters of a billion illnesses and 219,000 deaths each year around the globe. The Phase IIb, double-blind, randomised, placebo-controlled study will be assessing the efficacy of the candidate – via intramuscular administration

Continue Reading

Jardiance Reduces Risk of Progressive Kidney Disease in Patients with Type 2 Diabetes

New data showed Jardiance reduced the risk of new-onset or worsening kidney disease by 39% versus placebo when added to standard care in adults with type 2 diabetes with established cardiovascular disease. Boehringer Ingelheim and Lilly announced the findings at the American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans early in the month.

Continue Reading